Company overview
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing ACET with another company.
| Daily close (USD) | $5.74 |
| Market capitalization (USD) | $53,734,952.6 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.45 |
No matching rows. Clear the filter to see all records.
Read ACET's valuation metrics
Company size
Adicet Bio, Inc. Common Stock's recorded market capitalization is $53,734,952.6. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
ACET's recorded price-to-book ratio is 0.45. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Adicet Bio, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about ACET. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ACET's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.